MX2025004433A - Combinaciones de un degradador selectivo del receptor de estrogenos (serd) para el tratamiento del cancer - Google Patents
Combinaciones de un degradador selectivo del receptor de estrogenos (serd) para el tratamiento del cancerInfo
- Publication number
- MX2025004433A MX2025004433A MX2025004433A MX2025004433A MX2025004433A MX 2025004433 A MX2025004433 A MX 2025004433A MX 2025004433 A MX2025004433 A MX 2025004433A MX 2025004433 A MX2025004433 A MX 2025004433A MX 2025004433 A MX2025004433 A MX 2025004433A
- Authority
- MX
- Mexico
- Prior art keywords
- serd
- inhibitor
- patient
- cancer
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente descripción se relaciona con un método para tratar a un paciente con cáncer de mama positivo al receptor hormonal (HR+), negativo al receptor 2 del factor de crecimiento epidérmico humano (HER2-), que comprende administrar un degradador del receptor de estrógeno selectivo (SERD) oral en combinación con un inhibidor de AKT o un inhibidor de mTOR y/o un inhibidor de cinasa 4/6 dependiente de ciclina (CDK4/6i) al paciente que lo necesite.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263379835P | 2022-10-17 | 2022-10-17 | |
| US202363487744P | 2023-03-01 | 2023-03-01 | |
| PCT/EP2023/078625 WO2024083716A1 (en) | 2022-10-17 | 2023-10-16 | Combinations of a serd for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025004433A true MX2025004433A (es) | 2025-05-02 |
Family
ID=88506964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025004433A MX2025004433A (es) | 2022-10-17 | 2025-04-15 | Combinaciones de un degradador selectivo del receptor de estrogenos (serd) para el tratamiento del cancer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4604957A1 (es) |
| JP (1) | JP2025535154A (es) |
| KR (1) | KR20250089532A (es) |
| CN (1) | CN120051280A (es) |
| AU (1) | AU2023362285A1 (es) |
| IL (1) | IL320302A (es) |
| MX (1) | MX2025004433A (es) |
| TW (1) | TW202430176A (es) |
| WO (1) | WO2024083716A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| JP2026518466A (ja) * | 2023-06-02 | 2026-06-08 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体分解剤とakt阻害剤との組み合わせ |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| CN121646481A (zh) * | 2024-07-04 | 2026-03-10 | 海创药业股份有限公司 | 一种雌激素受体降解剂和akt抑制剂联合用药物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200736260A (en) | 2005-11-10 | 2007-10-01 | Smithkline Beecham Corp | Inhibitors of Akt activity |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| US8383607B2 (en) | 2010-03-31 | 2013-02-26 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
| TWI784255B (zh) | 2014-12-18 | 2022-11-21 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| UA125824C2 (uk) | 2016-10-24 | 2022-06-15 | Астразенека Аб | 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| TWI702219B (zh) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| CN114206345A (zh) * | 2019-08-12 | 2022-03-18 | 豪夫迈·罗氏有限公司 | 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌 |
| CA3151330A1 (en) * | 2019-09-16 | 2021-03-25 | Christina CURTIS | Methods of treatments based upon molecular characterization of breast cancer |
| US20210330653A1 (en) * | 2020-04-24 | 2021-10-28 | Astrazeneca Ab | Dosage Regimen for the Treatment of Cancer |
-
2023
- 2023-10-16 WO PCT/EP2023/078625 patent/WO2024083716A1/en not_active Ceased
- 2023-10-16 TW TW112139392A patent/TW202430176A/zh unknown
- 2023-10-16 EP EP23793256.1A patent/EP4604957A1/en active Pending
- 2023-10-16 AU AU2023362285A patent/AU2023362285A1/en active Pending
- 2023-10-16 KR KR1020257016241A patent/KR20250089532A/ko active Pending
- 2023-10-16 CN CN202380073258.1A patent/CN120051280A/zh active Pending
- 2023-10-16 IL IL320302A patent/IL320302A/en unknown
- 2023-10-16 JP JP2025521977A patent/JP2025535154A/ja active Pending
-
2025
- 2025-04-15 MX MX2025004433A patent/MX2025004433A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120051280A (zh) | 2025-05-27 |
| EP4604957A1 (en) | 2025-08-27 |
| TW202430176A (zh) | 2024-08-01 |
| JP2025535154A (ja) | 2025-10-22 |
| WO2024083716A1 (en) | 2024-04-25 |
| IL320302A (en) | 2025-06-01 |
| AU2023362285A1 (en) | 2025-05-29 |
| KR20250089532A (ko) | 2025-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration | Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials | |
| SG146666A1 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
| EP4295899A3 (en) | Apparatus for fat and cellulite reduction using rf energy in combination with magnetic muscle thermostimulation (ems) | |
| WO2004112890A3 (en) | Method for intraoperative radiation treatment of breast cancer | |
| IL214373A0 (en) | Use of adipose tissue-derived cells in the preparation of a composition for the treatment of cardiovascular diseases | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| PT1100488E (pt) | Utilizacao de compostos de creatina para tratamento das celulas e tecidos do osso ou cartilagem | |
| EP2332555A3 (en) | Methods of using regenerative cells to promote wound healing | |
| EP4649916A3 (en) | System comprising surgical guide, drill and detachable guide body | |
| WO2007014090A3 (en) | Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| MX2025005711A (es) | Metodos de tratamiento del cancer de mama con degradadores selectivos del receptor de estrogeno (serds) | |
| Lee et al. | Orbital floor and infraorbital rim reconstruction after total maxillectomy using a vascularized calvarial bone flap | |
| ATE485783T1 (de) | Vorrichtung zur interstitiellen laserbehandlungvon kleinen brustkrebsgeschwülsten und damit verbundene therapie | |
| Iconomou et al. | Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial | |
| WO2006022612A3 (en) | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| UA81689C2 (ru) | Способ предоперационного лечения послеоперационной боли бупренорфином | |
| EA200001014A3 (ru) | Лекарственное средство для лечения пациентов с опийной наркоманией и способ их лечения | |
| Barak et al. | Treatment of osteoradionecrosis combined with pathologic fracture and osteomyelitis of the mandible with electromagnetic stimulation | |
| WO2006014162A3 (en) | Methods of using regenerative cells in the treatment of renal diseases and disorders | |
| Ori et al. | Clarification of a suspension technique for unstable nasal bones | |
| Randoll et al. | The role of complex biophysical—chemical therapies for cancer | |
| Chezhian et al. | Management of osteoradionecrosis of oral cavity. | |
| MX2024007015A (es) | Inhibidor de cdk4 y 6 en combinacion con fulvestrant para el tratamiento del cancer de mama avanzado o metastasico con receptor hormonal positivo y receptor 2 del factor de crecimiento epidermico humano negativo en pacientes tratados anteriormente con un inhibidor de cdk4 y 6. |